



US010517880B2

**(12) United States Patent**  
**Dhuppad et al.****(10) Patent No.: US 10,517,880 B2****(45) Date of Patent: \*Dec. 31, 2019****(54) STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE****(71) Applicant: GLENMARK SPECIALTY S.A., La Chaux-de-Fonds (CH)****(72) Inventors: Ulhas R. Dhuppad, Maharashtra (IN); Ashok Katkurwar, Maharashtra (IN); Yashwant Gupta, Maharashtra (IN); Rajesh Ankam, Maharashtra (IN); Chandrakant Dhatrak, Maharashtra (IN)****(73) Assignee: GLENMARK SPECIALTY S.A., La Chaux-de-Fonds (CH)****(\*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 14 days.  
  
This patent is subject to a terminal disclaimer.**(21) Appl. No.: 15/703,801****(22) Filed: Sep. 13, 2017****(65) Prior Publication Data**

US 2018/0000842 A1 Jan. 4, 2018

**Related U.S. Application Data****(63)** Continuation of application No. 15/210,692, filed on Jul. 14, 2016, now Pat. No. 9,937,189, which is a continuation-in-part of application No. 15/183,534, filed on Jun. 15, 2016, now Pat. No. 9,750,754, which is a continuation of application No. 14/662,128, filed on Mar. 18, 2015, now Pat. No. 9,370,483, which is a continuation-in-part of application No. 14/483,837, filed on Sep. 11, 2014, now Pat. No. 9,078,923, which is a continuation-in-part of application No. PCT/IB2014/064251, filed on Sep. 4, 2014.**(30) Foreign Application Priority Data**

Sep. 13, 2013 (IN) ..... 2975/MUM/2013

**(51) Int. Cl.****A61K 31/58** (2006.01)  
**A61K 31/335** (2006.01)  
**A61K 9/00** (2006.01)  
**A61K 9/10** (2006.01)  
**A61K 47/36** (2006.01)  
**A61K 47/38** (2006.01)**(52) U.S. Cl.**CPC ..... **A61K 31/58** (2013.01); **A61K 9/0043** (2013.01); **A61K 9/10** (2013.01); **A61K 31/335** (2013.01); **A61K 47/36** (2013.01); **A61K 47/38** (2013.01)**(58) Field of Classification Search**

CPC .. A61K 2300/00; A61K 31/335; A61K 31/58; A61K 47/38; A61K 9/0043; A61K 47/36; A61K 9/10; A61K 31/00; A61K 31/573; A61K 47/02; A61K 47/186; A61K 47/26; A61P 27/14

See application file for complete search history.

**(56) References Cited**

## U.S. PATENT DOCUMENTS

4,871,865 A 10/1989 Lever, Jr. et al.  
4,923,892 A 5/1990 Lever, Jr. et al.  
5,837,699 A 11/1998 Sequeira et al.  
6,127,353 A 10/2000 Yuen et al.  
6,841,146 B2 1/2005 Haslwanter et al.  
7,977,376 B2 7/2011 Singh et al.  
8,399,508 B2 3/2013 Singh et al.  
9,078,923 B2 \* 7/2015 Dhuppad ..... A61K 9/0043  
9,370,483 B2 6/2016 Dhuppad et al.  
9,750,754 B2 \* 9/2017 Dhuppad ..... A61K 31/58  
10,016,443 B2 \* 7/2018 Khairatkar-Joshi ... A61K 31/58  
2004/0097474 A1 5/2004 Cagle et al.  
2006/0110328 A1 5/2006 Cagle et al.  
2007/0099883 A1 5/2007 Calis et al.  
2008/0058296 A1 3/2008 Chaudry  
2012/0121653 A1 5/2012 Jenkins et al.  
2013/0252929 A1 9/2013 Lee et al.  
2015/0099725 A1 4/2015 Khairatkar-Joshi et al.  
2015/0272966 A1 10/2015 Khairatkar-Joshi et al.

## FOREIGN PATENT DOCUMENTS

WO WO-1995020393 A1 8/1995  
WO WO-2001026658 4/2001  
WO WO-2006057769 A2 6/2006  
WO WO-2007095041 A2 8/2007  
WO WO-2008012338 A2 1/2008  
WO WO-2009003199 A1 12/2008  
WO WO-2010025236 A1 3/2010  
WO WO-2010042701 A2 4/2010

(Continued)

## OTHER PUBLICATIONS

Avicel® RC-591, Product Specification Bulletin, Feb. 2009.

(Continued)

Primary Examiner — Audrea B Coniglio

**(74) Attorney, Agent, or Firm** — Blank Rome LLP**(57) ABSTRACT**

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

**33 Claims, No Drawings**